Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy

This study has been completed.
Sponsor:
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT01086956
First received: March 12, 2010
Last updated: November 10, 2010
Last verified: November 2010
  Purpose

The purpose of this study is to compare metabolic and stress responses in combined general/epidural anesthesia in geriatric cancer patients.


Condition Intervention
Prostatic Cancer
Drug: epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Diagnostic
Official Title: Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy

Resource links provided by NLM:


Further study details as provided by Yonsei University:

Primary Outcome Measures:
  • plasma glucose, insulin, cortisol, epinephrine, norepinephrine, prolactin [ Time Frame: from preoperative baseline to postoperative 24 hours ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: September 2008
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elective RRP for prostatic cancer scheduled in the morning (9-11 a.m.)
  • patients aged more than 65 years
  • ASA physical status I or II
  • absence of contraindications to epidural approach
  • absence of a history of chronic pain or opioid medication

Exclusion Criteria:

  • contraindication to epidural catheterization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01086956

Locations
Korea, Republic of
Severance Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Yonsei University
  More Information

No publications provided by Yonsei University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kil Hae Keum, Yonsei University College of Medicine, Seoul, Republic of Korea
ClinicalTrials.gov Identifier: NCT01086956     History of Changes
Other Study ID Numbers: 4-2008-0319
Study First Received: March 12, 2010
Last Updated: November 10, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by Yonsei University:
patients of prostatic cancer aged more than 65 years

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Ropivacaine
Sufentanil
Adjuvants, Anesthesia
Analgesics
Analgesics, Opioid
Anesthetics
Anesthetics, General
Anesthetics, Intravenous
Anesthetics, Local
Central Nervous System Agents
Central Nervous System Depressants
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014